NO20016341L - Inhibitors for the integrin <alfa> v <beta> 6 - Google Patents

Inhibitors for the integrin <alfa> v <beta> 6

Info

Publication number
NO20016341L
NO20016341L NO20016341A NO20016341A NO20016341L NO 20016341 L NO20016341 L NO 20016341L NO 20016341 A NO20016341 A NO 20016341A NO 20016341 A NO20016341 A NO 20016341A NO 20016341 L NO20016341 L NO 20016341L
Authority
NO
Norway
Prior art keywords
asp
leu
arg
xer
phe
Prior art date
Application number
NO20016341A
Other languages
Norwegian (no)
Other versions
NO20016341D0 (en
Inventor
Alfred Jonczyk
Beate Diefenbach
Ulrich Groth
Gunther Zischinsky
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20016341D0 publication Critical patent/NO20016341D0/en
Publication of NO20016341L publication Critical patent/NO20016341L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Oppfinnelsen vedrører nye peptider med formel (I) : Ac-Arg-X^Asp-X^X^XXNH, som er biologisk aktive som ligander for integrinet ctvP, hvor: Ac er acetyl; Xer Ser, Gly, Thr, Asp, Arg, Val, Tyr, His ellerla;er Leu, Ile, Nie, Val eller Phe;er Asp, Glu, Lys, Phe, Aib, Nal, Gly, Ala, Bgl eller Phg; Xer Gly, Ala, Ser, PAla eller co-Abu; Xer Leu, Ile,ie, Val eller Phe; og Xer Arg, Har, Lys, Leu, Orn, Phe, Ala, Tyr, Gly, Ser eller Asp, hvorved de ovenfor nevnte amino-syrer kan være derivatiserte. Amino-syreradikalene er bundet til hverandre på en peptidlignende måte via a-amino-gruppene og a-karboksygruppene. Så vel de dekstrodreiende former og de levo-dreiende former av de optisk aktive aminosyreradikaler som saltene av peptidene er omfattet. Ac-Arg-Thr-Asp-Leu-Asp-Ser-Leu-Arg-NHer utelukket. Peptidene ifølge oppfinnelsen kan også anvendes som effektive inhibitorer for-integrinreseptoren, og således for behandling av forskjellige sykdommer og patologiske funn.The invention relates to novel peptides of formula (I): Ac-Arg-X 2, Asp-X 2, X Xer Ser, Gly, Thr, Asp, Arg, Val, Tyr, His ellerla; er Leu, Ile, Nie, Val or Phe; er Asp, Glu, Lys, Phe, Aib, Nal, Gly, Ala, Bgl or Phg; Xer Gly, Ala, Ser, PAla or co-Abu; Xer Leu, Ile, ie, Val or Phe; and Xer Arg, Har, Lys, Leu, Orn, Phe, Ala, Tyr, Gly, Ser or Asp, whereby the above-mentioned amino acids may be derivatized. The amino acid radicals are linked to each other in a peptide-like manner via the α-amino groups and the α-carboxy groups. Both the dextrorotatory forms and the levorotatory forms of the optically active amino acid radicals as well as the salts of the peptides are included. Ac-Arg-Thr-Asp-Leu-Asp-Ser-Leu-Arg-NHs excluded. The peptides of the invention can also be used as effective inhibitors of the pre-integrin receptor, and thus for the treatment of various diseases and pathological findings.

NO20016341A 1999-06-26 2001-12-21 Inhibitors for the integrin <alfa> v <beta> 6 NO20016341L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19929410A DE19929410A1 (en) 1999-06-26 1999-06-26 New octapepide compounds as alpha v beta 6 integrin inhibitors useful for treating and diagnosing heart disease, tumors, osteoporosis, fibrosis, inflammation, infection and psoriasis
PCT/EP2000/005404 WO2001000660A1 (en) 1999-06-26 2000-06-13 INHIBITORS OF THE INTEGRIN αvβ¿6?

Publications (2)

Publication Number Publication Date
NO20016341D0 NO20016341D0 (en) 2001-12-21
NO20016341L true NO20016341L (en) 2002-02-25

Family

ID=7912712

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016341A NO20016341L (en) 1999-06-26 2001-12-21 Inhibitors for the integrin <alfa> v <beta> 6

Country Status (17)

Country Link
EP (1) EP1189930A1 (en)
JP (1) JP2003503422A (en)
KR (1) KR20020015704A (en)
CN (1) CN1358195A (en)
AR (1) AR024472A1 (en)
AU (1) AU771099B2 (en)
BR (1) BR0011954A (en)
CA (1) CA2377224A1 (en)
CZ (1) CZ20014484A3 (en)
DE (1) DE19929410A1 (en)
HU (1) HUP0201729A3 (en)
MX (1) MXPA01013247A (en)
NO (1) NO20016341L (en)
PL (1) PL352374A1 (en)
SK (1) SK18722001A3 (en)
WO (1) WO2001000660A1 (en)
ZA (1) ZA200200673B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
CA2515127A1 (en) * 2003-02-06 2004-08-19 Alfred Jonczyk Peptidic sulfonamides
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
AU2007348941B2 (en) 2006-08-03 2011-08-04 Medimmune Limited Antibodies directed to alphaVbeta6 and uses thereof
JOP20190084B1 (en) * 2016-11-01 2023-09-17 Arrowhead Pharmaceuticals Inc Alpha-v beta-6 integrin ligands and uses thereof
JP7445594B2 (en) 2017-11-01 2024-03-07 アローヘッド ファーマシューティカルズ インコーポレイテッド Integrin ligands and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2103139A1 (en) * 1991-05-14 1992-11-15 George A. Heavner Peptide inhibitors of inflammation
ES2311131T3 (en) * 1997-08-08 2009-02-01 The Regents Of The University Of California TREATMENT OF HEPATIC FIBROSIS WITH ANTIBODIES AGAINST INTEGRIN ALFA-V-BETA6.
EP1140989A1 (en) * 1998-12-19 2001-10-10 MERCK PATENT GmbH Alpha(v) beta(6) integrin inhibitors

Also Published As

Publication number Publication date
JP2003503422A (en) 2003-01-28
NO20016341D0 (en) 2001-12-21
HUP0201729A2 (en) 2002-08-28
HUP0201729A3 (en) 2005-01-28
CA2377224A1 (en) 2001-01-04
CZ20014484A3 (en) 2002-04-17
KR20020015704A (en) 2002-02-28
CN1358195A (en) 2002-07-10
AU6263000A (en) 2001-01-31
AR024472A1 (en) 2002-10-02
SK18722001A3 (en) 2002-05-09
WO2001000660A1 (en) 2001-01-04
MXPA01013247A (en) 2002-07-02
ZA200200673B (en) 2003-04-24
BR0011954A (en) 2002-05-07
EP1189930A1 (en) 2002-03-27
PL352374A1 (en) 2003-08-25
AU771099B2 (en) 2004-03-11
DE19929410A1 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
US5192746A (en) Cyclic cell adhesion modulation compounds
ES2680022T3 (en) Peptide fragments to induce extracellular matrix protein synthesis
DE10075019I2 (en) New proteins with TNF inhibitory activity and their production.
CN101855235B (en) Protective skin care tetrapeptides
CA2370289A1 (en) Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
JP2006028195A (en) Peptide inhibitor of fibronectin and related collagen-binding protein
DK165988B (en) MODIFIED EGLINES B AND C, THEIR USE AS PROTEASE INHIBITORS, PROCEDURES FOR PREPARING IT, AND PHARMACEUTICAL PREPARATIONS CONTAINING THE MODIFIED EGLINES B AND C
ATE106449T1 (en) INHIBITION OF THE N-END RULE RESPONSE PATHWAY IN LIVING CELLS.
AR006517A1 (en) POLYPEPTIDE THAT REACHES A TOTAL AROUND 30 AMINO ACIDS; RESULTANT SUBSTANCE, PEPTIDOMIMETICO AND PHARMACEUTICAL COMPOSITION; USES OF THE POLYPEPTIDE AND PROCESS FOR THE SYNTHESIS OF THE POLYPEPTIDE.
WO2001005810A3 (en) CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN αVβ¿6?
NO20016341L (en) Inhibitors for the integrin &lt;alfa&gt; v &lt;beta&gt; 6
EP0421367B1 (en) Anticoagulant peptides
AU641215B2 (en) Stabilized sulfonate, sulfate, phosphonate and phosphate derivatives of hirudin
US5192747A (en) Anticoagulant peptides
US5039790A (en) Bioactive fragment of interleukin-1-B that has antagonistic activity
KR910009730A (en) Peptide
HUP0003357A2 (en) Cyclic azapeptides with angiogenic effect, pharmaceutical compositions comprising them, processes for producing thereof and their use
AU640502B2 (en) Analogs of hirudin having antiplatelet activity
MXPA04007170A (en) Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis.
RU99116976A (en) MYELOPEPTIDES AND THEIR THERAPEUTIC USE
AU2676399A (en) Novel cystine knot protein and materials and methods for making it
RU95120588A (en) CYCLOGEXAEPEPTIDES, THEIR MIXTURES, METHOD FOR PRODUCING AND USING THEM
JPH08269090A (en) New peptide
Sheh et al. Studies of the synthesis, immunology, and cytotoxicity of a cyclic octapeptide corresponding to TNF-. alpha.-(59-66)
TH57872B (en) Inhibitors of Intragrin Alpha Nubeta 6

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application